## Infection

Study	Country	Design		VE (95% CI)
Link-Gelles et al. (99)	USA	TN	<b>├■</b>	0.43 (0.39, 0.46)
Huiberts et al. (102)	Holland	С	<u>■</u>	0.20 (-0.07, 0.40)
Link-Gelles et al. (100)	USA	TN	<b>├──</b>	0.43 (0.29, 0.55)
Shrestha et al. (43)	USA	С	<u> </u>	0.04 (-0.12, 0.18)
			-0.25 0 0.25 0.5 0.75  Vaccine Effectiveness (VE)	1

## **Hospitalization/Severe Disease**

Study	Country	Design		VE (95% CI)
Surie et al. (9)	USA	TN	<b>├──</b>	0.73 (0.52, 0.85)
Tenforde et al. (98)	USA	TN	<del></del>	0.48 (0.30, 0.62)
Andersson et al. (35)	Nordics	MC	<b>├-■-</b>	0.74 (0.69, 0.79)
Andersson et al. (35)	Nordics	MC	<del>  ■</del>	0.80 (0.70, 0.92)
Lin et al. (10)	USA	С	<del>  ■</del>	0.59 (0.44, 0.70)
Fabiani et al. (101)	Italy	С	⊢■⊢	0.59 (0.55, 0.63)
Arbel et al. (11)	Israel	С	<del>  ■  </del>	0.81 (0.57, 0.92)
Poukka et al. (36)	Finland	С		0.57 (0.34, 0.67)
			-0.25 0 0.25 0.5 0.75 1 Vaccine Effectiveness (VE)	